For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230405:nRSE5183Va&default-theme=true
RNS Number : 5183V Venture Life Group PLC 05 April 2023
5April 2023
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Group")
Director Dealings
Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the international self-care market, announces
that Mark Adams, Non-Executive Director, today purchased 58,504 ordinary
shares of 0.3p each in the Company ("Ordinary Shares") at a volume weighted
average price of 42.73 pence per Ordinary Share.
Following this purchase, Mr Adams beneficially holds 58,504 Ordinary Shares
representing approximately 0.05 per cent. of the Company's issued share
capital.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cenkos Securities plc (Nomad and Broker) +44 (0) 20 7397 8900
Stephen Keys / Camilla Hume
Russell Kerr / Michael Johnson (Sales)
Singer Capital Markets (Joint Broker) +44 (0) 20 7496 3000
Shaun Dobson / Alaina Wong (Corporate Finance)
Jonathan Dighe (Sales)
About Venture Life (www.venture-life.com (http://www.venture-life.com/) )
Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, The Netherlands and Italy,
the Group's product portfolio includes some key products such as the UltraDEX
and Dentyl oral care product ranges, food supplements for maintaining brain
function, medical devices for women's intimate healthcare, fungal infections
and proctology, and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands, these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.
Through its Development & Manufacturing business in Italy, Biokosmes, the
Group also provides development and manufacturing services to companies for
consumer healthcare products, primarily medical devices.
The Company makes the following disclosures in accordance with article 19(3)
of the Market Abuse Regulation:
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Mark Adams
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Venture Life Group plc
b) LEI 213800S8CZUPLAB2KC70
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.3p each in Venture Life Group plc
Identification code
GB00BFPM8908
b) Nature of the transaction Purchase of ordinary shares
c) Price(s) and volume(s) Price Volume
42.74p 23,397
42.71p 23,412
42.75p 11,695
d) Aggregated information See above
- Aggregated volume
- Price
e) Date of the transaction 5 April 2023
f) Place of the transaction London Stock Exchange
d)
Aggregated information
- Aggregated volume
- Price
See above
e)
Date of the transaction
5 April 2023
f)
Place of the transaction
London Stock Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFLFEFSIIEIIV